Dr. Kirstein is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kirstein's full profile

Already have an account?

Summary

  • I retired from family medicine 7/31/13 and am working full time at Advanced Clinical Research (801-542-8190 ext 109). ACR is a stand alone clinical research facility where we do a wide variety of research studies on chronic conditions, such as gout, HTN, DM, as well as new vaccines, such as Dengue fever, smallpox, botulism, rabies.
    I also do acupuncture part time at the ACR office (3590 West 9000 South, Suite 300, West Jordan). Patients are welcome to call the number listed above for appointment. I do not do acu for weight loss.

Education & Training

  • University of Utah
    University of UtahResidency, Family Medicine, 1978 - 1981
  • David Geffen School of Medicine at UCLA
    David Geffen School of Medicine at UCLAClass of 1978

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2018 - 2022
  • UT State Medical License
    UT State Medical License 1979 - 2022
  • American Board of Family Medicine Family Medicine

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Une Nouvelle Étude De Phase III Montre Une Efficacité Significativement plus Grande Chez Les Enfants De 6 Mois À 24 Mois Qui Reçoivent Un Vaccin Avec Adjuvant Contre La Grippe (aQIV)
    Une Nouvelle Étude De Phase III Montre Une Efficacité Significativement plus Grande Chez Les Enfants De 6 Mois À 24 Mois Qui Reçoivent Un Vaccin Avec Adjuvant Contre La Grippe (aQIV)September 12th, 2017
  • New Phase III Study Shows Significantly Greater Efficacy in Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (aQIV)
    New Phase III Study Shows Significantly Greater Efficacy in Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (aQIV)September 11th, 2017
  • Moderna Phase 3 Trial Data Shows 94 Percent Efficacy Against COVID-19
    Moderna Phase 3 Trial Data Shows 94 Percent Efficacy Against COVID-19December 5th, 2020

Professional Memberships

Hospital Affiliations